Care Partners’ Perceptions of Amyloid-Targeting Therapy and Treat‑to‑Clearance for Alzheimer’s Disease in Japan: A Qualitative Study

Abstract Introduction Donanemab has been developed as an amyloid-targeting therapy (ATT) for mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD). In registration trials involving donanemab, a treat‑to‑clearance approach was used, in which patients discontinued ATT when...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Sadao Katayama, Masashi Tsujimoto, Keisuke Suzuki, Kaname Ueda, Kanako Shimoura, Shintaro Suo, Naohisa Hatakeyama
Format:	Artigo
Jezik:	Inglês
Izdano:	Adis, Springer Healthcare 2025-11-01
Serija:	Neurology and Therapy
Teme:	Alzheimer’s disease Amyloid-targeting therapy Burden Care partners Dementia Dose cessation
Online dostop:	https://doi.org/10.1007/s40120-025-00869-w
Oznake:	Označite Brez oznak, prvi označite!